Body Protection Compound Research

BPC-157:
The Repair
Peptide

A 15-amino acid partial sequence of body protection compound found in human gastric juice. One of the most studied peptides for tissue repair, anti-inflammatory, and neuroprotective properties.

How It Works Research Areas
BPC157Info icon
15aa
Amino Acids
300+
Animal Studies
1993
First Isolated
⚠️

This site is for research and informational purposes only. BPC-157 is not FDA-approved for human use and was added to the FDA's list of bulk drug substances of concern in 2022. Consult a licensed physician for any medical decisions.

// Quick Reference

BPC-157 at a Glance

Full Name
Body Protection Compound
Partial sequence of a protein isolated from human gastric juice. Naturally endogenous.
Structure
15-mer
15 amino acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Stability
High
Stable in gastric acid — unlike many peptides, BPC-157 is not readily degraded in the digestive tract, relevant to oral bioavailability research.
Research Depth
300+
Over 300 animal studies across multiple species. Human clinical trials have been conducted in Croatia but with limited publication.

// Repair Pathways

How BPC-157 Works

🩹
Angiogenesis Promotion
BPC-157 consistently upregulates VEGF (vascular endothelial growth factor) expression, promoting new blood vessel formation at injury sites. This enhanced vascularization is considered central to its accelerated healing effects in tendon, muscle, and bone research.
🔇
Nitric Oxide System Modulation
BPC-157 interacts with the NO system — both stimulating eNOS under conditions where NO is needed for healing and modulating the system to counter NO-related toxicity. This dual modulation is considered a key mechanism in its gastroprotective effects.
🧬
Growth Factor Upregulation
Research demonstrates upregulation of several growth factors beyond VEGF, including EGF and its receptor. Fibroblast activation and collagen synthesis enhancement have been documented in multiple wound healing studies.
🛡️
Cytoprotection
Named for its gastroprotective properties — BPC-157 counteracts damage from NSAIDs, alcohol, and corticosteroids to GI tissue. The mechanism involves local cytoprotection distinct from classical prostaglandin pathways.
⚡
Dopamine & Serotonin Modulation
BPC-157 has demonstrated effects on dopaminergic and serotonergic systems in the brain in animal models — relevant to the growing interest in its potential neuroprotective and mood-modulating properties.
BPC-157 15-mer VEGF / Angiogenesis NO System Growth Factors Gastroprotection Cytoprotection Dopamine / CNS

// Research Areas

What the Research Shows

Tendon & Ligament
Accelerated Tendon Healing
Multiple rat studies have demonstrated BPC-157 significantly accelerates healing of transected tendons and ligaments. Collagen synthesis, vascularization, and functional recovery all improved vs. control groups.
Consistent Animal Data
Gastrointestinal
GI Tract Protection
The original area of research — BPC-157's gastroprotective effects against NSAID, ethanol, and stress-induced ulcers are among the most replicated findings. Croatian clinical trials reported GI benefits in humans.
Clinical Data Available
Muscle Repair
Skeletal Muscle Recovery
Research in crush injury and surgical muscle damage models shows BPC-157 promotes faster functional recovery. Satellite cell activation and enhanced vascularization are proposed mechanisms.
Moderate Animal Data
Bone Healing
Fracture Healing
Studies in bone fracture and segmental bone defect models demonstrate BPC-157 accelerates callus formation and bone remodeling. Effects appear synergistic with standard orthopedic interventions.
Multiple Animal Models
Neuroprotection
CNS & Peripheral Nerve
Peripheral nerve crush injury studies show improved recovery with BPC-157. Brain dopaminergic and serotonergic effects have been documented in animal models, sparking interest in neurological applications.
Emerging Research
Cornea & Eye
Corneal Healing
Applied topically, BPC-157 has demonstrated accelerated healing of corneal injuries in animal models — one of the few application routes studied beyond systemic administration.
Topical Applications

// Regulatory Status

Current Legal Status

FDA Watch List (2022)

In 2022, the FDA added BPC-157 to its list of bulk drug substances that may not be used in compounding. This effectively restricted US compounding pharmacies from producing BPC-157 for human use, significantly impacting its clinical availability.

Updated: 2022 · FDA 503A/503B Bulk Substances
Research Compound Status

BPC-157 remains legally available as a research chemical in the United States and many other countries. It is not scheduled as a controlled substance. Research use in preclinical settings is ongoing worldwide.

Research chemical · Not scheduled
Croatian Clinical Trials

Croatian researchers who first characterized BPC-157 have conducted human clinical trials, primarily for GI conditions. Some trials have been registered and results published, representing the primary human clinical data available for this compound.

Human data available · GI applications
International Availability

BPC-157 regulatory status varies by country. It is not approved anywhere as a pharmaceutical drug. Outside the US, compounding availability varies. The regulatory landscape is actively evolving — check current local regulations.

Varies by jurisdiction · Evolving
300+
studies.
Still
researched.

BPC-157 has one of the largest animal research bases of any experimental peptide. Its consistent healing and cytoprotective effects across multiple tissue types and injury models have made it one of the most discussed compounds in regenerative research — despite its complex regulatory status.

PubMed Research →